Explore more publications!
Educators Post Observer
Got News to Share?

Press Releases

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
December 9, 2025

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

Indeterminate GlobeNewswire, Inc.
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
December 9, 2025

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Indeterminate GlobeNewswire, Inc.
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in…
December 8, 2025

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in…

Indeterminate GlobeNewswire, Inc.
Stanton University Extends Tuition Freeze Through 2026–2027 to Ease Financial Strain on Students
December 8, 2025

Stanton University Extends Tuition Freeze Through 2026–2027 to Ease Financial Strain on Students

Neutral EIN Presswire
New Children’s Book and Courses Help Kids Build Confidence, Resilience, and Emotional Strength
December 8, 2025

New Children’s Book and Courses Help Kids Build Confidence, Resilience, and Emotional Strength

Neutral EIN Presswire
Machine Learning Course for Software Engineers: Interview Kickstart Launches Structured 8-Month ML Program for Career Transition
December 8, 2025

Machine Learning Course for Software Engineers: Interview Kickstart Launches Structured 8-Month ML Program for Career Transition

Indeterminate GlobeNewswire, Inc.
Community Invited to 2026 MLK Day Celebration at Kennett High School
December 8, 2025

Community Invited to 2026 MLK Day Celebration at Kennett High School

Neutral EIN Presswire
WISER Crosses 50,000 Student Registrations in India’s Largest Quantum Training Initiative
December 8, 2025

WISER Crosses 50,000 Student Registrations in India’s Largest Quantum Training Initiative

Neutral EIN Presswire
School Management System Market to Expand at a 14.6% CAGR by 2029, Reaching US $38.45 Billion
December 8, 2025

School Management System Market to Expand at a 14.6% CAGR by 2029, Reaching US $38.45 Billion

Neutral EIN Presswire
School Management Software Market to Grow at 17% CAGR from 2025-2029
December 8, 2025

School Management Software Market to Grow at 17% CAGR from 2025-2029

Neutral EIN Presswire
SafeSpace Global (SSGC) Announces Strategic Partnership With 911inform to Transform School Safety Across America
December 8, 2025

SafeSpace Global (SSGC) Announces Strategic Partnership With 911inform to Transform School Safety Across America

Indeterminate GlobeNewswire, Inc.
Aura Minerals Completes Feasibility Study for the Era Dorada Project
December 8, 2025

Aura Minerals Completes Feasibility Study for the Era Dorada Project

Indeterminate GlobeNewswire, Inc.
‘The Moors in Spain: The Freedom Fighters’ Short Animated Film Screened at Oak Park River Forest High School
December 8, 2025

‘The Moors in Spain: The Freedom Fighters’ Short Animated Film Screened at Oak Park River Forest High School

Neutral EIN Presswire
NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
December 8, 2025

NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio

Indeterminate GlobeNewswire, Inc.
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
December 8, 2025

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Indeterminate GlobeNewswire, Inc.
Naval Aviator Turned NPS Doctoral Student Earns National Recognition for Applied Quantum Research
December 7, 2025

Naval Aviator Turned NPS Doctoral Student Earns National Recognition for Applied Quantum Research

Neutral EIN Presswire
The Greene School Students Begin Two-Year Journey: Assembly of RV-12 Aircraft Underway
December 5, 2025

The Greene School Students Begin Two-Year Journey: Assembly of RV-12 Aircraft Underway

Neutral EIN Presswire
Cumulative Life Adversity May Predict Severity of Early Alcohol Abstinence Symptoms and Clinical Outcomes
December 8, 2025

Cumulative Life Adversity May Predict Severity of Early Alcohol Abstinence Symptoms and Clinical Outcomes

Neutral EIN Presswire
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
December 6, 2025

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Indeterminate GlobeNewswire, Inc.
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
December 6, 2025

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Indeterminate GlobeNewswire, Inc.
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions